Traitement préemptif de la réactivation de l’hépatite virale B des patients sous chimiothérapie anticancéreuse
Abstract It is estimated that one third of the world population has been in contact with the hepatitis B virus (HBV) with a prevalence that varies according to geographic area. This prevalence is more prevalent among patients with neoplasic disease. Thus, the risk of viral reactivation of hepatitis B virus during or after chemotherapy is […]